Targeting epigenetics in diabetic cardiomyopathy: Therapeutic potential of flavonoids - 08/12/22
, Qing Ni a, ⁎ Abstract |
The pathophysiological mechanisms of diabetic cardiomyopathy have been extensively studied, but there is still a lack of effective prevention and treatment methods. The ability of flavonoids to protect the heart from diabetic cardiomyopathy has been extensively described. In recent years, epigenetics has received increasing attention from scholars in exploring the etiology and treatment of diabetes and its complications. DNA methylation, histone modifications and non-coding RNAs play key functions in the development, maintenance and progression of diabetic cardiomyopathy. Hence, prevention or reversal of the epigenetic alterations that have occurred during the development of diabetic cardiomyopathy may alleviate the personal and social burden of the disease. Flavonoids can be used as natural epigenetic modulators in alternative therapies for diabetic cardiomyopathy. In this review, we discuss the epigenetic effects of different flavonoid subtypes in diabetic cardiomyopathy and summarize the evidence from preclinical and clinical studies that already exist. However, limited research is available on the potential beneficial effects of flavonoids on the epigenetics of diabetic cardiomyopathy. In the future, clinical trials in which different flavonoids exert their antidiabetic and cardioprotective effects through various epigenetic mechanisms should be further explored.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Flavonoids treat diabetic cardiomyopathy by targeted epigenetic modification.
Flavonoids treat diabetic cardiomyopathy by targeted epigenetic modification.ga1Le texte complet de cet article est disponible en PDF.
Highlights |
• | Epigenetic regulation plays an important role in the pathophysiology of DCM. |
• | Flavonoids have good pharmaceutical potential and are a major source of epigenetic modulators. |
• | Flavonoids can target epigenetic mechanisms to prevent and treat DCM. |
• | Future clinical studies on flavonoids through epigenetic modifications for the treatment of DCM should be strengthened to realize the translation of mechanistic studies to clinical applications. |
Abbreviations : DCM, AGEs, DM, T2DM, DPP-4, SGLT-2, GLP-1, PI3K, Akt, Nrf2, NF-κB, MAPK, O-GlcNAcylation, PPAR-α, EGCG, DNMTs, PGC-1α, TNF-α, SERCA2a, RAAS, AT1b, HATs, HDACs, NLRP3, IL-1β, IL-6, α-SMA, CAMKII, HDACi, HMTs, HMGA1, PPAR-γ, CEBPα, ROS, TXNIP, COX2, TGF-β, lncRNAs, JNK/SAPK, EMT, FoxO3, PIK3CA, ARC, VDAC1, MALAT1, AHR, MIAT, α-MHC, ANP, BNP, MCP-1, DHM, CBP, mTOR, EC, IRS-1, IGF1R, Ang II, I/R, OHdG
Keywords : Diabetic Cardiomyopathy, Flavonoids, Epigenetics
Plan
Vol 157
Article 114025- janvier 2023 Retour au numéro
Article précédent
- Applications and research progress of Traditional Chinese medicine delivered via nasal administration
- Hongping Hou, Yujie Li, Ziying Xu, Zihui Yu, Bo Peng, Caixia Wang, Wei Liu, Wei Li, Zuguang Ye, Guangping Zhang
- The application of antidepressant drugs in cancer treatment
- Yunxi Zheng, Xu Chang, Yuyang Huang, Dingwen He
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?